Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam versus propofol for postoperative recovery after painless gastroscopy
ChiCTR2100043306Phase 4Recruiting
- Sponsor
- Subei People's Hospital
- Start
- Jan 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of remimazolam, propofol and remifentanil (2 arms), sponsored by Subei People's Hospital. Primary endpoints: Incidence, severity, and duration of 12 major postoperative discomfort symptoms, Incidence, severity, and duration of other postoperative discomfort symptoms and 1 more. Started Jan 2021; status: recruiting.
02
Drugs
remimazolampropofolremifentanil
Beyond the preview
Go deeper on ChiCTR2100043306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043306.